Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
UCSF Helen Diller Family Comprehensive Cancer Center · University of California, San Francisco · +32 more institutions
Abstract
Abiraterone acetate, an androgen biosynthesis inhibitor, improves overall survival in patients with metastatic castration-resistant prostate cancer after chemotherapy. We evaluated this agent in patients who had not received previous chemotherapy.
In this double-blind study, we randomly assigned 1088 patients to receive abiraterone acetate (1000 mg) plus prednisone (5 mg twice daily) or placebo plus prednisone. The coprimary end points were radiographic progression-free survival and overall survival.
Citation impact
- FWCI
- 174.92
- Percentile
- 100%
- References
- 28
Authors
33- CJCharles J. RyanCorresponding
UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco
- MRMatthew R. Smith
Massachusetts General Hospital
- JSJohann S. de Bono
Royal Marsden Hospital, Institute of Cancer Research
- AMArturo Molina
Janssen (Belgium)
- CJChristopher J. Logothetis
The University of Texas MD Anderson Cancer Center
Topics & keywords
- Prednisone
- Medicine
- Abiraterone acetate
- Hazard ratio
- Prostate cancer
- Internal medicine
- Interim analysis
- Urology
- Good health and well-being